Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sinopharm’s COVID-19 vaccine is 86% effective, according to UAE regulators

By Brian Buntz | December 10, 2020

SinopharmThe United Arab Emirates has approved a COVID-19 vaccine from Sinopharm (OTCMKTS:SHTDY). The China-based pharma company concluded that that the vaccine was 86% effective, putting it ahead of the vaccine performance of the vaccine candidate from AstraZeneca (LON:AZN) but behind the vaccines from Pfizer (NYSE:PFE) and Moderna (NYSE:MRNA). Both of the latter two vaccines were 95% efficacious. 

The UAE Ministry of Health stated that clinical trial data confirmed that the vaccine had no serious safety concerns. Furthermore, the vaccine was 100% effective at fending off moderate and severe COVID-19 infections. 

Sinopharm’s vaccine also does not require storage in ultra-cold temperatures, unlike Pfizer’s vaccine. 

The United Arab Emirates’ decision to allow emergency use of the vaccine marks the first time a country outside of China has approved its use. Morocco is also planning a Sinopharm-based vaccination program. 

Given its use in China, the Sinopharm COVID-19 vaccine is likely the most extensively used globally, with nearly one million people receiving it to date. 

But China, like Russia, had made the vaccine available before Phase 3 clinical trials had concluded. In Nov., Sinopharm submitted the vaccine for final approval. 

In related news, the Sinopharm competitor Sinovac is facing controversy for allegations that its CEO has bribed China drug authorities for vaccine approvals, according to the Washington Post. 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, coronavirus, covid-19, COVID-19 vaccine, Moderna, Pfizer, Sinopharm
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50